Category: Biology

It seems even the sex industry is not immune to chemophobia, according to a recent Greenpeace Netherlands announcement, users of PVC sex toys destined for orificial use should not. Use them, that is.

According to Greenpeace, these plastic devices can contain “extremely high concentrations of phthalate plasticisers which allegedly pose a risk to human health and the environment”. The organisation wants the European Union to ban the use of phthalates in sex toys as it already has done with phthalates previously used in the manufacturer of PVC childrens’ toys.

The Daily Telegraph reports how, “The environmental group said it was shocked to find that seven of the eight sex toys it had tested contained between 24 and 51 per cent of phthalates.”

Their actual report shows that individual phthalates in a range of products are at at trace amounts. They do report the presence of 490 g per kilo of di-isodecyl phthalate (DIDP) in one device as determined by GC/MS.

There is so much disinformation about phthalates on the web, that it is almost impossible to track down the actual levels of additives used as primary plasticisers in PVC products. I’d assume the percentage needs to be relatively high to make the devices we’re currently discussing “plastic” enough, but 51% seems very high regardless.

Moreover, where are the tests revealing how much of this “shocking” percentage might actually leach out of such a device during normal usage? And, even if there is a degree of leaching, does that correlate with actual risk to health. These questions are yet to be answered for any devices whether sex toys, children’s toys or medical devices.

Any thoughts?

On Friday, August 18, Barr Laboratories asked the US Food and Drugs Administration to reconsider its application to make its Plan B contraceptive available over the counter. According to FierceBiotech’s John Carroll, “Given the FDA’s sudden willingness to work out a marketing plan for the contraceptive, Barr has a good shot at finally obtaining an approval that should have come through in 2004.” Carroll reckons that the FDA now has the opportunity to show the US that science and not ideology controls how therapeutics are reviewed. “Given the Bush administration’s clear preference for ideology,” Carroll says, “the FDA may have more difficulties ahead. But for now, there’s reason for hope.”

Plan B is an “emergency” contraceptive, backup birth control, in other words, a form of contraception often referred to as a morning after pill. It comes in the form of two levonorgestrel pills, which are taken orally after unprotected sex. Plan B reduces the risk of pregnancy. Those who oppose it on ideological grounds posit that it is tantamount to an abortion despite the fact that the timescale within which it must be used can be shorter than the time within which conception generally occurs.

More on Plan B from the FDA here. The FDA announced at the end of July that, “It is proceeding to work with [Barr] to resolve the remaining policy issues associated with the marketing of Plan B as an over-the-counter option.”

Will keep you posted on this or you can subscribe for free to FierceBiotech to get the low down.

Heart drugs are proving rather useful to pharma companies hoping to find lucrative treatments of another kind of disorder, that maybe involves the heart, but mostly involves the loins.

A heart drug that went into clinical trials in the 1990s has become the linchpin for efforts to develop a medication to treat female sexual arousal disorder (FSAD), researchers are reporting. An estimated 40 percent of women have FSAD or another form of female sexual dysfunction, the difficulty or inability to find satisfaction in sexual expression.

Compounds that sustain the activity of vasoactive intestinal peptide (VIP) are a major target of drug research efforts. VIP controls blood flow to the vagina, and decreased blood flow is believed to be one factor in female sexual dysfunction. VIP is degraded in the body by several enzymes, including an enzyme called NEP. Blocking NEP thus allows VIP to continue working.

David Pryde and colleagues at Pfizer in the UK (the company that brought us Viagra) began work with Candoxatril, a powerful NEP inhibitor tested in the 1990s for chronic heart failure. By re-engineering Candoxatril’s molecular structure, they developed a compound with the key actions needed for an FSAD drug.

The new compound blocks NEP, takes effect rapidly, and continues having an effect for a relatively short time. “The compound demonstrates excellent efficacy in a rabbit model of sexual arousal and was expected to be similarly efficacious in humans,” the researchers state in the Journal of Medicinal Chemistry. The compound is undergoing clinical evaluation as a potential treatment for FSAD.